Pueraria Lobata and Pueraria Thomsonii for Mild Dyslipidemia

• Status: Not yet recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease. Maintaining normal levels of lipid indicators can significantly reduce the risk of atherosclerotic cardiovascular disease and mortality. Empirical evidence suggests that adherence to Pueraria lobata and Pueraria thomsonii is useful for improving dyslipidemia, but evidence from randomized controlled trials is lacking. This randomized, double-blind controlled trial is therefore designed to evaluate the efficacy and safety of Pueraria lobata and Pueraria thomsonii for dyslipidemia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangxi University of Traditional Chinese Medicine

Criteria

Inclusion Criteria:

• Marginally elevated low-density lipoprotein (LDL-C), 3.4 to 4.1 mmol/L

• Informed consent to the study and signed the informed consent form

Exclusion Criteria:

• Patients who have a history of allergy to Pueraria Lobata or Pueraria Thomsonii.

• Patients who have taken lipid-lowering drugs within a week

• Patients with secondary dyslipidemia caused by other diseases or medications taken.

• Pregnant or lactating women.

• Patients who combine cognitive dysfunction, disorders of consciousness, psychiatric disorders, dyslexia or verbal communication dysfunction

• Patients with a combination of other serious diseases, such as malignant tumors, hepatic or renal insufficiency, cardiovascular or cerebrovascular disease, etc.